

**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Johannes Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
David Pisetsky

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.384

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 1899** Complex disease = complex trial? Lessons from a successful trial of anti-IFN $\alpha$  in SLE  
*R van Vollenhoven*

**Viewpoint**

- 1902** Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission  
*M A D'Agostino, L Terslev, R Wakefield, M Østergaard, P Balint, E Naredo, A Iagnocco, M Backhaus, W Grassi, P Emery*

**Clinical and epidemiological research**

- 1909** Sifalimumab, an anti-interferon- $\alpha$  monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study  
*M Khamashta, J T Merrill, V P Werth, R Furie, K Kalunian, G G Illei, J Drappa, L Wang, W Greth, on behalf of the CD1067 study investigators*
- 1917** Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)  
*Y Kaneko, T Atsumi, Y Tanaka, M Inoo, H Kobayashi-Haraoka, K Amano, M Miyata, Y Murakawa, H Yasuoka, S Hirata, H Nagasawa, E Tanaka, N Miyasaka, H Yamanaka, K Yamamoto, T Takeuchi*

- 1924** Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts  
*S Ajeeganova, J H Humphreys, M K Verheul, H W van Steenberghe, J A B van Nies, I Hafström, B Svensson, T W J Huizinga, L A Trouw, S M M Verstappen, A H M van der Helm-van Mil*

- 1933** Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment  
*K Delli, E A Haacke, F G M Kroese, R P Pollard, S Ihrler, B van der Vegt, A Vissink, H Bootsma, F K L Spijkervet*

- 1939** Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study  
*W Kievit, N van Herwaarden, F H J van den Hoogen, R F van Vollenhoven, J W J Bijlsma, B J F van den Bemt, A van der Maas, A A den Broeder*

- 1945** Development of the ClinESSDAL: a clinical score without biological domain. A tool for biological studies  
*R Seror, P Meiners, G Baron, H Bootsma, S J Bowman, C Vitali, J-E Gottenberg, E Theander, A Tzioufas, S De Vita, M Ramos-Casals, T Dörner, L Quartuccio, P Ravaut, X Mariette, on behalf of the EULAR Sjögren Task Force*

- 1951** Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim  
*S Tan, A Dasgupta, J Yao, J A Flynn, L Yao, M M Ward*

- 1958** Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group  
*R G W Lambert, P A C Bakker, D van der Heijde, U Weber, M Rudwaleit, K-G A Hermann, J Sieper, X Baraliakos, A Bennett, J Braun, R Burgos-Vargas, M Dougados, S J Pedersen, A G Jurik, W P Maksymowych, H Marzo-Ortega, M Østergaard, D Poddubnyy, M Reijnen, F van den Bosch, I van der Horst-Bruinsma, R Landewé*

- 1964** Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials  
*K Zou, J Wong, N Abdullah, X Chen, T Smith, M Doherty, W Zhang*

- 1971** Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis  
*T O Smith, K Zou, N Abdullah, X Chen, S R Kingsbury, M Doherty, W Zhang, P G Conaghan*

- 1979** Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings  
*M C Genovese, F Yang, M Østergaard, N Kinnman*

- 1984** Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)  
*A Kavanaugh, L Puig, A B Gottlieb, C Richlin, Y You, S Li, M Song, B Randazzo, P Rahman, I B McInnes*

**Basic and translational research**

- 1989** Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology  
*C Huesca, A C Ortiz, L Dunning, L McGavin, L Bennett, K McIntosh, A Crilly, M Kurowska-Stolarska, R Plevin, R J van 't Hof, A D Rowan, I B McInnes, C S Goodyear, J C Lockhart, W R Ferrell*

**MORE CONTENTS ►**

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



equator network



When you have finished with this please recycle it



The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 1998** IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus

M Zhao, Y Zhou, B Zhu, M Wan, T Jiang, Q Tan, Y Liu, J Jiang, S Luo, Y Tan, H Wu, P Renauer, M del M A Gutiérrez, M J C Palma, R O Castro, C Fernández-Roldán, E Raya, R Faria, C Carvalho, M E Alarcón-Riquelme, Z Xiang, J Chen, F Li, G Ling, H Zhao, X Liao, Y Lin, A H Sawalha, Q Lu

- 2007** Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production

Y Deng, J Zhao, D Sakurai, A L Sestak, V Osadchiy, C D Langefeld, K M Kaufman, J A Kelly, J A James, M A Petri, S-C Bae, M E Alarcón-Riquelme, G S Alarcón, J-M Anaya, L A Criswell, B I Freedman, D L Kamen, G S Gilkeson, C O Jacob, J T Merrill, P M Gaffney, K M Sivits, T B Niewold, R Ramsey-Goldman, J D Reveille, R H Scofield, A M Stevens, S A Boackle, L M Vilá, I I W Sohn, S Lee, D-M Chang, Y W Song, T J Vyse, J B Harley, E E Brown, J C Edberg, R P Kimberly, R M Cantor, B H Hahn, J M Grossman, B P Tsao

- 2014** Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification

M E Munroe, R Lu, Y D Zhao, D A Fife, J M Robertson, J M Guthridge, T B Niewold, G C Tsokos, M P Keith, J B Harley, J A James

- 2022** Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis

M F König, J T Giles, P A Nigrovic, F Andrade

- 2029** Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes

J Imgenberg-Kreuz, J K Sandling, J C Almlöf, J Nordlund, L Signér, K B Norheim, R Omdal, L Rönnblom, M-L Eloranta, A-C Syvänen, G Nordmark

- 2037** Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis

N-Y Lin, A Distler, C Beyer, A Philippi-Schöbinger, S Breda, C Dees, M Stock, M Tomcik, A Niemeier, F Dell'Accio, K Gelse, M P Mattson, G Schett, J H W Distler

- 2045** Pleiotropic roles of metallothioneins as regulators of chondrocyte apoptosis and catabolic and anabolic pathways during osteoarthritis pathogenesis

Y Won, Y Shin, C-H Chun, Y Cho, C-W Ha, J-H Kim, J-S Chun



## Letters

- 2053** Clinical efficacy of  $\alpha 4$  integrin block with natalizumab in ankylosing spondylitis

F Ciccà, A Rizzo, G Guggino, R Bignone, M Galia, G Triolo

- 2054** Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: earlier identification but more severe patient reported outcomes

W P Nieuwenhuis, M PT de Wit, A Boonen, A H M van der Helm-van Mil

## Electronic pages

### Correspondence

- e72** Differential roles of TGF- $\beta$  signalling in joint tissues during osteoarthritis development

T Y Wang, D Chen

- e73** Could abatacept directly target expanded plasmablasts in IgG4-related disease?

G C Alegria, P Pochar, J-O Pers, D Cornec

- e74** Response to: 'Could abatacept directly target expanded plasmablasts in IgG4-related disease?' by Alegria *et al*

M Yamamoto, H Takahashi, K Takano, T Himi, H Nakase